Last €0.19 EUR
Change Today +0.001 / 0.52%
Volume 179.4K
BTH1V On Other Exchanges
Symbol
Exchange
Helsinki
Berlin
OTC US
As of 11:29 AM 10/22/14 All times are local (Market data is delayed by at least 15 minutes).

biotie therapies oyj (BTH1V) Snapshot

Open
€0.19
Previous Close
€0.19
Day High
€0.20
Day Low
€0.19
52 Week High
11/1/13 - €0.36
52 Week Low
08/13/14 - €0.18
Market Cap
88.5M
Average Volume 10 Days
256.0K
EPS TTM
€-0.01
Shares Outstanding
456.0M
EX-Date
03/30/06
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOTIE THERAPIES OYJ (BTH1V)

Related News

No related news articles were found.

biotie therapies oyj (BTH1V) Related Businessweek News

No Related Businessweek News Found

biotie therapies oyj (BTH1V) Details

Biotie Therapies Corp. operates as a drug development company. It focuses on the development of drugs for neurodegenerative and psychiatric disorders, such as Parkinson’s disease, Alzheimer’s disease and other cognitive disorders, alcohol and drug dependence (addiction), and post-traumatic stress disorder; and inflammatory and fibrotic liver diseases. The company has a development portfolio with various small molecule and biological drug candidates at various stages of clinical development. Its advanced product, Selincro (nalmefene) reduces alcohol consumption in adult patients with alcohol dependence who have a high level of alcohol consumption. The company’s drug development projects also include Tozadenant (SYN115), an oral, potent, and selective adenosine A2a receptor antagonist in Phase 3 development, which enters the brain and modulates regions associated with motor and non-motor function; SYN120, an oral, potent, and selective antagonist of the 5-HT6 receptor, which has completed single and multiple ascending dose Phase 1 clinical studies and a Phase 1 positron emission tomography imaging study to determine therapeutic dose; and BTT-1023 (VAP-1 antibody) that has completed Phase Ib clinical trials for the treatment of rheumatoid arthritis and psoriasis. In addition, its drug development projects comprise Nepicastat (SYN117), a cocaine dependence enzyme dopamine beta hydroxylase inhibitor focusing on conducting Phase 2 clinical trial; and Ronomilast, an oral phosphodiesterase-4 inhibitor with therapeutic potential in chronic inflammatory disorders. The company has strategic collaboration with UCB Pharma S.A. Biotie Therapies Corp. is based in Turku, Finland.

34 Employees
Last Reported Date: 07/30/14

biotie therapies oyj (BTH1V) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

biotie therapies oyj (BTH1V) Key Developments

H.Lundbeck A/S Brings Biotie's Selincro on the Market in Germany

Biotie announced that its partner H.Lundbeck A/S (Lundbeck) has brought Selincro on the market in Germany. According to the terms of the license agreement between Biotie and Lundbeck for Selincro, Biotie is eligible for a milestone payment of EUR 2 million related to the market entry. Lundbeck will continue the rollout of Selincro in additional European markets during 2014.

Biotie Therapies Corp. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Biotie Therapies Corp. reported unaudited earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported revenue of EUR 0.8 million against EUR 2.1 million a year ago. Net loss attributable to parent company shareholders was EUR 3.7 million against EUR 4.0 million a year ago. Cash flow used in operating activities EUR 4.3 million against EUR 0.5 million a year ago. Basic and diluted loss per share was EUR 0.01 against EUR 0.01 a year ago. Operating loss was EUR 3.566 million compared to the EUR 3.891 million for the same quarter year ago. Loss before taxes was EUR 3.697 compared to the EUR 4.026 million for the same quarter year ago. For the six months, the company reported revenues of EUR 5.9 million against EUR 17.4 million a year ago. Net loss attributable to parent company shareholders was EUR 5.3 million against net profit of EUR 6.0 million a year ago. Cash flow used in operating activities was EUR 9.6 million against EUR 10.7 million a year ago. Basic and diluted loss per share was EUR 0.01 against earnings per share of EUR 0.01 a year ago. Operating loss was EUR 4.951 million compared to the EUR 6.168 million for the same period year ago. Loss before taxes was EUR 5.279 compared to the EUR 5.970 million for the same period year ago. Investments in tangible assets was EUR 0.128 million compared to the EUR 0.018 million for the same period year ago. Investments in intangible assets was EUR 0.166 million compared to the EUR 0.152 million for the same period year ago.

Biotie Updates Outlook on Tozadenant and SYN120 into Phase 3 Development

Biotie has decided to advance tozadenant, its adenosine A2a receptor antagonist for Parkinson's disease, into Phase 3 development as part of the company's proprietary portfolio. SYN120 to advance into Phase 2 in Parkinson's disease dementia, further strengthening Biotie's presence in Parkinson's disease space. Preparations for Phase 3 development are ongoing, and it is expected that the Phase 3 clinical studies can commence recruitment in first half of 2015, as originally planned. Following the decision by UCB Pharma S.A. to return global rights to tozadenant in March 2014, the company has been evaluating the most suitable development strategy for this Phase 3 ready asset to maximize its value to shareholders and has concluded that this can be best achieved by continuing with the Phase 3 study within its current portfolio. The Company considers tozadenant to potentially be its most valuable asset given the high unmet medical need in Parkinson's disease and stage of development and is currently evaluating various options, which may include a capital increase, to support the clinical studies and a strong regulatory filing package for tozadenant. As announced in July 2014, the company has received a USD 2.0 million (EUR 1.5 million) grant from The Michael J. Fox Foundation (MJFF) for a Phase 2 study in Parkinson's disease dementia. The study is currently expected to begin recruitment around the end of 2014. As a result of this grant and the decision on tozadenant, the previously planned Phase 2 study in Alzheimer's disease will not begin recruitment by the end of 2014 and will be assessed based on the development status of the other products within its portfolio.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BTH1V:FH €0.19 EUR +0.001

BTH1V Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BTH1V.
View Industry Companies
 

Industry Analysis

BTH1V

Industry Average

Valuation BTH1V Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.1x
Price/Book 1.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOTIE THERAPIES OYJ, please visit www.biotie.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.